Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Defactinib in Resectable Malignant Pleural Mesothelioma
NCT04201145Phase 1Withdrawn
- Start
- Sep 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of defactinib in malignant pleural mesothelioma (MPM) (4 cohorts). Primary endpoints: Maximum Tolerated Duration at 56 days and Biomarker activity in response to the MTD at 56 days. Planned start Sep 2020; status: withdrawn.
02
Drugs
defactinib
03
Conditions
malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT04201145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04201145.